Amberstone Biosciences Secures $12 Million Series A Financing To Advance Immuno-Oncology Pipeline Of Tumor Microenvironment Activated Therapeutics

Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders.